Gyre Therapeutics, Inc. Payments to Acquire Debt Securities, Available-for-sale
Gyre Therapeutics, Inc. (GYRE) reported Payments to Acquire Debt Securities, Available-for-sale of $2.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-07
- 2026-06-30: Payments to Acquire Debt Securities, Available-for-sale 6 month $2.03M.
- 2025-06-30: Payments to Acquire Debt Securities, Available-for-sale 6 month $11.22M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 6 month |
|---|---|
| 2026-06-30 | $2.03M 10-Q · filed 2026-08-07 |
| 2025-06-30 | $11.22M 10-Q · filed 2026-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |